# High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)

> **NCT07285369** · NA · TERMINATED · sponsor: **Agyany Pharma LTD** · enrollment: 12 (actual)

## Conditions studied

- Gaucher Disease, Type 3

## Interventions

- **DRUG:** Ambroxol

## Key facts

- **NCT ID:** NCT07285369
- **Lead sponsor:** Agyany Pharma LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-03-01
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor stopped the study
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285369, "High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07285369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*